Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218263 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL218262 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL3259892 | 0.98 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL543358 | 0.98 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL1368802 | 0.98 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL27745869 | 0.91 | SLC15A1 (0.46) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12614963 | 0.88 | TSHR (0.46) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12614096 | 0.88 | TSHR (0.46) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12614965 | 0.88 | TSHR (0.46) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL19331556 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319660-B2 | Preparation of substituted diaminopyrazine dicarboxylic acids | MEDIBEACON INC. (US) | 2025-06-03 | — | — | US | claimed |
| EP-4313172-A1 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | Medibeacon Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117241839-A | Preparation of substituted diaminopyrazine dicarboxylic acids | 麦迪贝肯有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20220324818-A1 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | MEDIBEACON INC. | 2022-10-13 | — | — | US | claimed |
| WO-2022212077-A1 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | MEDIBEACON INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-4019528-B1 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | SHENZHEN YUNHE PHARMACEUTICAL TECH PARTNERSHIP LIMITED (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12491190-B2 | Bile acid derivative, composition and application thereof | SHENZHEN YUNHE PHARMACEUTICAL TECHNOLOGY PARTNERSHIP (LIMITED) (CN) | 2025-12-09 | — | — | US | disclosed |
| EP-3700578-B1 | SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12319660-B2 | Preparation of substituted diaminopyrazine dicarboxylic acids | MEDIBEACON INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-5972926-A | REACTING A DIAMINE DERIVATIVE WITH PYRIDINE OR PYRIZINE 2,3-DICARBOXYLIC ACID OR 2,3-CARBOXYLIC ANHYDRIDE, CONVERTING THE COMPOUND INTO A SALT, RESOLVING THE FORMED COMPOUND INTO ITS ISOMER | NYCOMED IMAGING AS (NO) | 1999-10-26 | — | — | US | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998043663-A1 | SANDRAMYCIN ANALOGS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-10-08 | — | — | WO | disclosed |
| US-5693772-A | PROTECTING ACID AND HYDROXY GROUPS OF BENANOMICIN A, REDUCTION OF AMIDE TO IMIDOESTER WITH MEERWEIN REAGENT, DEPROTECTING, REFLUXING IN ACETONE/WATER MIXTURE TO CLEAVE IMIDOESTER AND FORM CARBOXY GROUP | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1997-12-02 | — | — | US | disclosed |
| WO-1997042179-A1 | ANTIBACTERIAL AGENTS | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0799208-A1 | PYRIDINE AND PYRAZINEDICARBOXYLIC-ACID DERIVATIVES AS CELL PROLIFERATION REGULATORS | NYCOMED IMAGING AS (NO) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019457-A1 | PYRIDINE AND PYRAZINEDICARBOXYLIC-ACID DERIVATIVES AS CELL PROLIFERATION REGULATORS | NYCOMED IMAGING AS (NO) | 1996-06-27 | — | — | WO | disclosed |
| EP-0684253-A1 | DESALANINEBENANOMICIN A DERIVATIVE AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1995-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | ALDH1A1 4135/4885KMT2A 1017/4885MAPK1 202/4885 |
| US-12319660-B2 | Preparation of substituted diaminopyrazine dicarboxylic acids | DDC, DPYD, SDHA | ALDH1A1 205/4885KMT2A 1466/4885MAPK1 2650/4885 |
| US-20220324818-A1 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | DDC, DPYD, SDHA | ALDH1A1 205/4885KMT2A 1466/4885MAPK1 2650/4885 |
| US-12491190-B2 | Bile acid derivative, composition and application thereof | NR1H4, GPBAR1, GLP1R | ALDH1A1 4168/4885KMT2A 4487/4885MAPK1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.